Pfizer Inc. (PFE)
Health Care14 articles
Price chart
Pfizer Inc. (PFE) overview
Pfizer is one of the world’s largest pharmaceutical companies, developing vaccines and medicines across many therapeutic areas. It is a member of the S&P 500 and is classified in the Health Care sector — pharmaceutical, biotech, device and managed-care companies.
Pfizer Inc. trades on the NYSE under the ticker symbol PFE. As of the most recent market data, the stock was priced around $28.46, up 1.79% on the session, giving Pfizer Inc. a market capitalization of roughly $162.21B.
Over the past 52 weeks, PFE has traded between $23.58 and $28.75. Shares are valued at a trailing price-to-earnings (P/E) ratio of about 37.4, a common gauge of how richly the market prices the company's earnings. Pfizer Inc. also pays a dividend, currently yielding around 6.04%.
Key statistics
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Why investors watch PFE
As one of the larger companies in the Health Care sector, Pfizer Inc. is closely followed by investors and often moves with broader trends across pharmaceutical, biotech, device and managed-care companies. Traders watch PFE for earnings reports, analyst rating changes, and headlines that can shift sentiment — each of which is summarized on this page as it breaks.
Because the S&P 500 is weighted by market value, Pfizer Inc.'s size means its share-price moves can also nudge the index as a whole, making PFE a stock that even index investors pay attention to.
Market Mood
Latest PFE news
Pfizer Stock Predictions for 2030: Future Trends Examined
The article discusses predictions regarding Pfizer's (PFE) stock performance by 2030. It highlights various analysts' outlooks, mentioning insights into market changes and how these could potentially impact Pfizer's position. While specific figures for projected stock prices are not provided, the importance of understanding market trends and their implications for investor strategies is emphasized. This analysis is crucial for investors looking to make informed decisions about their portfolios based on long-term forecasts for Pfizer.
Read More: Pfizer Stock Predictions for 2030: Future Trends Examined
Pfizer (PFE) Earnings Report Upcoming Amid Dividend Concerns
Pfizer (PFE) is set to release its earnings report soon, which will be closely scrutinized alongside its dividend and pipeline developments. Investors are particularly interested in how the company's performance in these areas may impact its stock value moving forward. The scrutiny reflects the ongoing uncertainties regarding Pfizer's pipeline projects and their potential revenue contributions. This earnings report will be significant for investors as it could influence market sentiment regarding Pfizer’s financial health and future growth prospects.
Read More: Pfizer (PFE) Earnings Report Upcoming Amid Dividend Concerns
Energy Transfer (ET) Offers 6.6% Yield Amid AI Growth Catalyst
Energy Transfer (ET) presents an investment opportunity with a forward dividend yield of 6.6%. The company is targeting 3% to 5% annualized distribution growth and has historically increased payouts by 2% to 4% annually. Meanwhile, Pfizer (PFE) features a nearly 7% forward dividend yield and trades at a low P/E ratio of 8.5. Despite some risks, the metrics indicate potential value for long-term investors in these stocks, appealing for those seeking reliable dividend returns.
Read More: Energy Transfer (ET) Offers 6.6% Yield Amid AI Growth Catalyst
Pfizer (PFE) Offers 6.9% Dividend Yield Amid New Drug Development
Pfizer (PFE) has been identified as a solid dividend stock, currently offering a forward-looking dividend yield of 6.9%. The company is focused on developing new profit centers, including acquiring Seagen in 2023 to enhance its oncology pipeline. By 2030, Pfizer anticipates launching at least eight new blockbuster drugs, supported by both acquisitions and internal development. This potential for new drugs reinforces Pfizer's ability to continue providing dividends, which is important for investors seeking steady income.
Read More: Pfizer (PFE) Offers 6.9% Dividend Yield Amid New Drug Development
Trump's Generic Drug Tariffs to Hit 100% by August 2028
President Donald Trump announced that generic drugs imported into the U.S. will face a 100% tariff starting in August 2028, rising to 200% in August 2029, after an initial two-year period with zero tariffs beginning August 1, 2026. This phased tariff schedule aims to incentivize domestic production of generic drugs. The U.S. imports nearly 50% of its generics from India, which significantly relies on the U.S. market for pharmaceutical exports. Ordinary investors should monitor these changes as they may impact the profitability and operations of major drugmakers like Eli Lilly and Pfizer (PFE).
Read More: Trump's Generic Drug Tariffs to Hit 100% by August 2028
Pfizer (PFE) Trades at 8x Earnings, Seagen Integration Drives Growth
Pfizer (PFE) trades at 8x forward earnings and has a 7% dividend yield, positioning it as a cheaper option compared to Amgen's (AMGN) 17x rebuild multiple. In Q1 2026, Pfizer's oncology franchise generated $3.83 billion in revenue, a 9% year-over-year increase, driven by its Seagen deal and Padcev, which contributed $591 million, up 39%. In contrast, Amgen's key products saw significant declines, with Prolia down 34% and Enbrel down 37%. This dissonance in performance highlights the contrasting strategies, where Pfizer is monetizing existing assets while Amgen is working on rebuilding growth, impacting investor sentiment toward both companies.
Read More: Pfizer (PFE) Trades at 8x Earnings, Seagen Integration Drives Growth
Pfizer (PFE) Offers Attractive Dividend Yield for Investors
Pfizer (PFE) is recognized for its dividend payouts, appealing to income investors. The current dividend yield is noted to be an attractive feature for those seeking steady income streams. Pfizer's financial performance, specifically regarding its earnings per share, is expected to influence investor sentiment positively. This focus on dividends might impact its stock valuation as investors look for reliable income sources amidst market fluctuations.
Read More: Pfizer (PFE) Offers Attractive Dividend Yield for Investors
PFE and JNJ Annual Dividend Income of $3,540 for Investors
Investors holding 500 shares each of Pfizer (PFE) and Johnson & Johnson (JNJ) can expect an annual passive income of $3,540 on a $127,000 investment, with a blended yield of 2.79%. JNJ recently increased its quarterly dividend to $1.34, marking its 64th consecutive increase, supported by a AAA-rated balance sheet and $19.7 billion in free cash flow. Meanwhile, PFE's yield stands at 6.8%, reflecting stock compression. JNJ reported Q1 2026 revenues of $15.426 billion in pharmaceuticals, an 11.2% year-over-year increase, while MedTech revenue reached $8.636 billion, up 7.7%.
Read More: PFE and JNJ Annual Dividend Income of $3,540 for Investors
Pfizer (PFE) Stock Price Drops Over 50% Since Pandemic Peak
Pfizer (PFE) has experienced a stock price decline of over 50% since its peak during the COVID-19 pandemic. This significant drop is attributed to market adjustments after expectations of ongoing vaccine needs did not materialize, leading to decreased investor confidence. Additionally, Pfizer faces challenges with upcoming patent expirations through 2028 and has struggled to develop new drugs to replace those losing patent protection. The company’s recent decision to acquire a competitor with a promising GLP-1 drug may impact future growth prospects.
Read More: Pfizer (PFE) Stock Price Drops Over 50% Since Pandemic Peak
Pfizer (PFE) Analysts Show Caution Amid 50% Stock Decline
Currently, only 2 out of 29 analysts rate Pfizer (PFE) as strong buy, while over 60% suggest a cautious outlook with ratings of hold, underperform, or sell. The stock has declined more than 50% from its 2021 peak. Patent expirations for key drugs like Eliquis and Vyndaqel are expected to impact revenues significantly by 2028. Despite these challenges, Pfizer maintains a dividend yield of 6.6%, much higher than the market average of 1.1%. The company continues efforts in drug development, including acquiring a promising GLP-1 candidate after dropping its own.
Read More: Pfizer (PFE) Analysts Show Caution Amid 50% Stock Decline
Pfizer (PFE) Lacks Earnings Momentum According to Analyst Jim Cramer
Analyst Jim Cramer stated that Pfizer (PFE) does not have any current earnings momentum. This observation could indicate potential concerns regarding PFE’s future stock performance in the market. Without positive earnings momentum, investor confidence may decline, potentially affecting the stock's valuation. It is essential for investors to monitor PFE's earnings reports closely to gauge any changes in momentum.
Read More: Pfizer (PFE) Lacks Earnings Momentum According to Analyst Jim Cramer
Pfizer (PFE) Stock Down Over 50% from 2021 High Amid Challenges
Pfizer (PFE) stock is down over 50% from its 2021 high as demand for COVID vaccines decreases. The company is facing headwinds, including upcoming patent cliffs that could lead to revenue declines for key drugs. Despite this, Pfizer maintains a 6.4% dividend yield, with management stating that supporting the dividend is a key corporate goal. The company has taken steps to pivot towards GLP-1 weight-loss drugs and continues to develop its portfolio in oncology and migraine treatments, which could improve its market position in the future.
Read More: Pfizer (PFE) Stock Down Over 50% from 2021 High Amid Challenges
Pfizer (PFE) Receives FDA Approval for Veppanu Breast Cancer Drug
The FDA has approved Veppanu, a breast cancer pill developed by Pfizer (PFE) and Arvinas, for advanced cases. This approval is significant as it provides a new treatment option for patients in later stages of breast cancer, potentially impacting the market for cancer therapeutics. The details of its efficacy and safety profile are yet to be published but could influence investor sentiment and market dynamics in the pharmaceutical sector. The new drug's launch may bolster Pfizer's pipeline and revenue streams in oncology.
Read More: Pfizer (PFE) Receives FDA Approval for Veppanu Breast Cancer Drug
Pfizer (PFE) GLP-1 Drug Shows 10%-12% Weight Loss in Trials
Pfizer (PFE) has reported positive results from its GLP-1 drug PF-08653944, which shows weight loss of 10% to 12% by week 28 in Phase 2b trials. This drug features a monthly injection regimen, compared to the weekly doses of competitors like Novo Nordisk's Wegovy and Eli Lilly's Zepbound, which may increase patient adherence. The weight loss drug market is projected to grow at nearly 25% annually through 2035, indicating strong competitive potential for Pfizer. As alternatives emerge, the dynamics of the anti-obesity drug market may be shifting, impacting shares of incumbents like NVO and LLY.
Read More: Pfizer (PFE) GLP-1 Drug Shows 10%-12% Weight Loss in TrialsMore Health Care stocks
Frequently asked questions
Is Pfizer Inc. in the S&P 500?
Yes. Pfizer Inc. (PFE) is a member of the S&P 500 index, classified in the Health Care sector.
What sector is PFE in?
Pfizer Inc. is classified in the Health Care sector of the S&P 500 — pharmaceutical, biotech, device and managed-care companies.
Where can I find the latest PFE news?
This page collects recent Pfizer Inc. (PFE) news and market analysis, each article summarized by AI and tagged with bullish, bearish, or neutral sentiment.
What is Pfizer Inc.'s stock price?
As of the most recent market data, Pfizer Inc. (PFE) traded at approximately $28.46. Prices move throughout the trading day, so this reflects the latest available quote rather than a live price.
What is Pfizer Inc.'s market cap?
Pfizer Inc. has a market capitalization of roughly $162.21B, based on its most recent share price and shares outstanding.
What is PFE's P/E ratio?
PFE trades at a trailing price-to-earnings ratio of about 37.4. The P/E ratio compares a company's share price to its earnings per share.